Back to Search Start Over

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice

Authors :
Paolo Enrico Maltese
Gianluca Masi
Alfredo Falcone
Emanuele Canestrari
Antonio Russo
I. Stasi
Eliana Rulli
Mauro Magnani
Irene Floriani
Bruno Vincenzi
Lisa Salvatore
Giuseppe Tonini
Giuseppe Perrone
Francesca Andreoni
Annamaria Ruzzo
Maria Rosa Tommasino
Francesco Graziano
Fotios Loupakis
Daniele Santini
Giacomo Giulio Baldi
Santini, D
Loupakis, F
Vincenzi, B
Floriani, I
Stasi, I
Canestrari, E
Rulli, E
Maltese, PE
Andreoni, F
Masi, G
Graziano, F
Baldi, GG
Salvatore, L
Russo, A
Perrone, G
Tommasino, MR
Magnani, M
Falcone, A
Tonini, G
Ruzzo, A
Source :
Università di Pisa-IRIS
Publication Year :
2008

Abstract

Purpose. Several studies have suggested that KRAS somatic mutations may predict resistance to cetuximab- and panitumumab-based treatments in metastatic colorectal cancer (CRC) patients. Nevertheless, most experiences were conducted on samples from primaries. The aim of this study was to evaluate the grade of concordance in terms of KRAS status between primaries and related metastases. Patients and Methods. We analyzed KRAS codon 12 and 13 mutations from formalin-fixed sections of 107 CRC primaries and related metastases. Eight pairs were excluded from the analysis because of the low amount of tumor tissue in the available samples. The main characteristics were: 50 men, 49 women; median age at diagnosis, 71 years (range, 41–84). The metastatic sites analyzed were the liver in 80 patients (80.8%), lung in seven patients (7.1%), and other sites in 12 patients (12.1%). Results. A KRAS mutation was found in 38 (38.4%) primary tumors and in 36 (36.4%) related metastases. The rate of concordance was 96.0% (95% confidence interval, 90.0%–98.9%). Discordance was observed in only four (4%) patients. Conclusions. Our results indicate that the detection of KRAS mutations in either primary or metastatic tumors from patients with CRC is concordant and this assessment could be used to predict response to targeted therapies such as cetuximab and panitumumab. Learning Objectives After completing this course, the reader should be able to: Describe the importance of KRAS mutations in CRC patients.Explain the relevance to cancer treatment of concordance of KRAS status between primary tumors and metastases in CRC patients.Discuss the impact of KRAS mutations as a predictive/prognostic factor in CRC patients. CME This article is available for continuing medical education credit at http://CME.TheOncologist.com

Details

Language :
English
Database :
OpenAIRE
Journal :
Università di Pisa-IRIS
Accession number :
edsair.doi.dedup.....3bd5e7842f3493483883025602432b26